In preclinical animal models, the ipamorelin half life is approximately 2 hours (120 minutes) in plasma. Research peptide supplier PX1 Research provides high-purity ipamorelin manufactured in the USA, backed by lot-specific RP-HPLC/MS and endotoxin testing, with same-day dispatch from CA and AZ facilities.
In preclinical animal models, the ipamorelin half life is approximately 2 hours (120 minutes) in plasma. Research peptide supplier PX1 Research provides high-purity ipamorelin manufactured in the USA, backed by lot-specific RP-HPLC/MS and endotoxin testing, with same-day dispatch from CA and AZ facilities.
In vitro and preclinical pharmacokinetic assessments demonstrate that ipamorelin exhibits a short terminal plasma half-life of approximately 2 hours. As a synthetic pentapeptide growth hormone secretagogue (GHS), its rapid systemic elimination demands precise experimental design when evaluating receptor activation kinetics in laboratory models.
Unlike long-acting growth hormone releasing hormone (GHRH) analogues, ipamorelin produces a brief, transient peak in growth hormone (GH) elevation. Researchers analyzing pulsatile release profiles frequently track the rapid metabolism of ipamorelin via dipeptidyl peptidases and renal clearance pathways.
To maintain analytical consistency in clearance studies, researchers require lyophilized peptides characterized by high structural integrity. You can order 10 mg vials of Ipamorelin manufactured under strict cGMP protocols directly from PX1 Research to eliminate purity variables in your assay data.
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 and a molecular mass of approximately 711.86 g/mol. It belongs to the ghrelin mimetic class of growth hormone secretagogues and binds selectively to the growth hormone secretagogue receptor 1a (GHS-R1a).
Preclinical investigations demonstrate that ipamorelin is unique among first- and second-generation secretagogues due to its exceptional receptor selectivity. While earlier compounds such as GHRP-2 and GHRP-6 induce non-selective activation that increases systemic cortisol and prolactin levels, ipamorelin selectively stimulates GH release without significantly activating the adrenocorticotropic hormone (ACTH) or prolactin axes.
This receptor-level specificity allows investigators to isolate GH-driven metabolic, anabolic, and tissue-repair signaling mechanisms without confounding endocrine crosstalk. Detailed structural assays available in our peptide stability documentation outline the conformational stability of the Aib residue against enzymatic degradation.
In rodent, canine, and swine experimental models, the terminal elimination half-life of ipamorelin consistently measures between 1.8 and 2.2 hours following parenteral administration. Peak plasma concentration (Cmax) is attained rapidly, typically within 15 to 30 minutes post-administration, followed by a mono-exponential decay curve.
The primary elimination route for ipamorelin involves rapid cleavage by circulating endopeptidases and exopeptidases, followed by renal filtration of residual peptide fragments. Because the molecule contains N-terminal modification with alpha-aminoisobutyric acid (Aib), it exhibits greater resistance to aminopeptidase cleavage than native ghrelin, extending its bioactivity to the observed ~120-minute window.
When comparing clearance profiles across secretagogue classes, researchers often evaluate ipamorelin alongside short-acting GHRH mimetics like Sermorelin. However, because ipamorelin acts via GHS-R1a rather than the GHRH receptor, its clearance kinetics reflect distinct intracellular receptor internalization and recycling timelines.
The degradation rate of ipamorelin in laboratory settings is governed by environment, solvent choice, pH, and temperature. In reconstitutions using unbuffered sterile water or normal saline, the peptide backbone remains stable at 2–8°C for several weeks, whereas exposure to elevated temperatures accelerates hydrolysis of the C-terminal amide group.
Proteolytic degradation accelerates dramatically when ipamorelin is incubated in biological matrices such as serum or tissue homogenates containing active serine proteases. Experimental designs measuring receptor binding affinity must account for this rapid enzymatic decay by using protease inhibitor cocktails or maintaining low-temperature processing.
To ensure batch-to-batch consistency during long-term experimental protocols, laboratories routinely source high-purity ipamorelin accompanied by verified purity assessments and low endotoxin thresholds.
Evaluating secretagogue kinetics requires comparing terminal half-lives, receptor targets, and signal duration. The table and criteria below highlight key pharmacokinetic distinctions observed across common secretagogues in preclinical research:
1. Ipamorelin: Terminal half-life ~2 hours; targets GHS-R1a; induces pulsatile GH release with zero impact on cortisol or prolactin. 2. CJC-1295 No DAC: Terminal half-life ~30 minutes; targets GHRH receptor; produces immediate, short-lived GHRH pathway stimulation. 3. CJC-1295 with DAC: Terminal half-life ~6 to 8 days; binds serum albumin to extend plasma retention; creates continuous, non-pulsatile GH elevation. 4. GHRP-2: Terminal half-life ~1.5 to 2 hours; targets GHS-R1a; induces robust GH release accompanied by moderate cortisol and prolactin elevations.
When co-administered in dual-signaling models (GHRH + GHS-R1a crosstalk), ipamorelin and short-acting GHRH analogues display synergistic release profiles while preserving discrete clearance timelines. Explore our full growth hormone secretagogue collection to compare structural specifications.
Proper preparation of lyophilized ipamorelin is critical for preserving peptide concentration and preventing aggregation during pharmacokinetic assays. Lyophilized vials should be stored at -20°C prior to reconstitution.
Reconstitution should be performed using Bacteriostatic Water (containing 0.9% benzyl alcohol) or Sterile Bacteriostatic Sodium Chloride. Reagent should be introduced gently along the glass vial wall rather than sprayed directly onto the peptide cake to minimize mechanical shear stress.
Once reconstituted, ipamorelin solution should be aliquoted into polypropylene microcentrifuge tubes to prevent adsorption loss onto container surfaces during repeated freeze-thaw cycles. Stored at 2–8°C, reconstituted solutions maintain analytical integrity for up to 30 days. For bulk trial planning, review our bulk peptide procurement options.
Reliable kinetic data depends entirely on the chemical purity and accurate dosing of the starting material. Impurities such as truncated peptide sequences, residual TFA (trifluoroacetic acid), or high endotoxin levels corrupt receptor binding assays and alter observed elimination rates.
Essential quality verification criteria for research peptides include: - Reversed-Phase HPLC (RP-HPLC): Confirms purity (>98.0%) and detects truncated peptide impurities. - Mass Spectrometry (LC-MS): Verifies exact molecular mass (711.86 g/mol for ipamorelin). - Endotoxin Testing (LAL Assay): Ensures levels are below <0.05 EU/mg to prevent cellular inflammatory responses during in vitro assays. - USA Manufacturing & Traceability: Guarantees strict raw material control and lot-to-lot consistency.
Red flags to avoid when procuring secretagogues include suppliers who fail to provide lot-specific COAs, offer non-transparent mass spectrum data, or sell unverified imported materials. Examine verifiable quality benchmarks across our entire PX1 Research peptide catalog.
Quantifying the ipamorelin half life in animal models requires robust analytical detection methods capable of differentiating intact ipamorelin from its metabolic fragments. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) serves as the gold standard assay for plasma concentration tracking.
Blood samples collected at serial time points (e.g., 5, 15, 30, 60, 120, 240, and 360 minutes post-dose) are immediately treated with protease inhibitors and centrifuged at 4°C to isolate plasma. Internal standards are spiked into samples prior to solid-phase extraction (SPE) to maintain precision.
Non-compartmental pharmacokinetic analysis (NCA) is then applied to calculate key parameters, including area under the curve (AUC0-inf), clearance rate (CL/F), volume of distribution (Vd), and elimination half-life (t1/2). Obtaining accurate kinetic data requires starting with reference-grade material like PX1 Research Ipamorelin.
PX1 Research provides academic, clinical, and private laboratory facilities with analytical-grade ipamorelin packaged in sealed 5 mg and 10 mg lyophilized vials. Every lot undergoes rigorous third-party testing to guarantee identity, exact purity, and endotoxin compliance before release.
Orders placed before 3:00 PM EST Monday through Friday ship same-day from our dual logistics hubs in California and Arizona. Packages are dispatched in temperature-controlled, shock-resistant packaging with full domestic tracking to ensure compound stability upon arrival.
Access comprehensive analytical documentation, verified HPLC chromatograms, and lot COAs directly through our portal. Order analytical-grade Ipamorelin today to secure reliable materials for your research program.
ipamorelin half life
The terminal plasma half-life of ipamorelin in preclinical animal models is approximately 2 hours (120 minutes). It is rapidly cleared via enzymatic hydrolysis and renal excretion, producing a brief, selective pulse of growth hormone secretion.
What is the ipamorelin half life in animal models?
In preclinical rodent, canine, and swine models, ipamorelin exhibits an elimination half-life ranging between 1.8 and 2.2 hours. Peak concentration (Cmax) occurs within 15 to 30 minutes following administration.
How does the ipamorelin half life compare to CJC-1295?
Ipamorelin has a half-life of ~2 hours, whereas CJC-1295 No DAC has a shorter half-life of ~30 minutes. Conversely, CJC-1295 with DAC has an extended half-life of 6 to 8 days due to albumin binding.
Why is ipamorelin considered highly selective compared to GHRP-2 or GHRP-6?
In preclinical studies, ipamorelin binds selectively to GHS-R1a without stimulating ACTH, cortisol, or prolactin secretion, unlike GHRP-2 and GHRP-6 which induce non-selective endocrine elevation.
How should reconstituted ipamorelin be stored to prevent degradation?
Reconstituted ipamorelin should be kept refrigerated at 2–8°C in a sterile, buffered solution. Under these conditions, it remains stable for up to 30 days without significant loss of structural integrity.
Does reconstituted ipamorelin degrade rapidly at room temperature?
Yes, ambient room temperatures accelerate liquid hydrolytic pathways. Reconstituted ipamorelin left at room temperature degrades measurably within 24 to 48 hours, reducing experimental accuracy.
What assay methods verify ipamorelin sequence integrity and purity?
Analytical laboratories utilize Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity assessment and Mass Spectrometry (LC-MS) to verify molecular mass (711.86 g/mol).
Is ipamorelin legal to purchase for research purposes in the USA?
Yes, ipamorelin is fully legal to purchase across the United States for qualified laboratory, in vitro, and preclinical research applications when supplied by compliant scientific vendors.
Do you provide lot-specific COAs for ipamorelin vials?
Yes, every batch of ipamorelin sold by PX1 Research includes a downloadable, lot-specific Certificate of Analysis detailing RP-HPLC purity, MS mass verification, and endotoxin assay results.
How fast does PX1 Research ship ipamorelin orders?
Orders placed before 3:00 PM EST Monday through Friday ship same-day from fulfillment centers in California and Arizona, providing fast domestic transit with full tracking.
Can ipamorelin be combined with CJC-1295 No DAC in research assays?
In preclinical signaling research, ipamorelin and CJC-1295 No DAC are frequently co-administered to analyze the synergistic interaction between GHS-R1a and GHRH receptor pathways.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.